LTR Pharma Limited (ASX:LTP)
Australia
· Delayed Price · Currency is AUD
0.450
0.00 (0.00%)
At close: Mar 6, 2026
LTR Pharma Income Statement
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
| TTM
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
| Operating Revenue | 1.13 | 1.51 | 0.05 | - | - | - |
| Other Revenue | - | - | - | - | 0.01 | - |
| Revenue | 1.13 | 1.51 | 0.05 | - | 0.01 | - |
| Revenue Growth (YoY) | 126.42% | 2978.25% | - | - | - | - |
| Cost of Revenue | 4.53 | 2.79 | 3.51 | - | - | - |
| Gross Profit | -3.4 | -1.28 | -3.46 | - | 0.01 | - |
| Selling, General & Admin | 4.44 | 3.63 | 2.01 | 0.59 | 0.68 | 0.03 |
| Research & Development | - | - | - | 0.82 | 0.35 | - |
| Other Operating Expenses | 0.39 | 0.4 | 0.17 | 0.03 | - | - |
| Operating Expenses | 6.39 | 4.83 | 3.48 | 1.44 | 1.03 | 0.03 |
| Operating Income | -9.78 | -6.11 | -6.94 | -1.44 | -1.02 | -0.03 |
| Interest Expense | -0 | -0 | -0 | -0 | -0 | -0.01 |
| Interest & Investment Income | 1.11 | 0.6 | 0 | 0 | 0 | 0 |
| Earnings From Equity Investments | -0.26 | -0.06 | - | - | - | - |
| Currency Exchange Gain (Loss) | -0.02 | -0.02 | -0.01 | -0.02 | -0.01 | -0 |
| Pretax Income | -8.95 | -5.59 | -6.95 | -1.45 | -1.03 | -0.04 |
| Net Income | -8.95 | -5.59 | -6.95 | -1.45 | -1.03 | -0.04 |
| Net Income to Common | -8.95 | -5.59 | -6.95 | -1.45 | -1.03 | -0.04 |
| Shares Outstanding (Basic) | 181 | 167 | 139 | 260 | - | - |
| Shares Outstanding (Diluted) | 181 | 167 | 139 | 260 | - | - |
| Shares Change (YoY) | 23.89% | 19.96% | -46.34% | - | - | - |
| EPS (Basic) | -0.05 | -0.03 | -0.05 | -0.01 | - | - |
| EPS (Diluted) | -0.05 | -0.03 | -0.05 | -0.01 | - | - |
| Free Cash Flow | -6.96 | -4.45 | -5.09 | -1.54 | -0.57 | -0.03 |
| Free Cash Flow Per Share | -0.04 | -0.03 | -0.04 | -0.01 | - | - |
| Gross Margin | - | -84.75% | - | - | 100.00% | - |
| Operating Margin | -864.79% | -404.86% | -14162.27% | - | -11195.03% | - |
| Profit Margin | -791.01% | -370.83% | -14192.25% | - | -11314.40% | - |
| Free Cash Flow Margin | -615.44% | -294.96% | -10396.58% | - | -6258.86% | - |
| EBITDA | -9.78 | -6.1 | -6.94 | - | - | - |
| D&A For EBITDA | 0 | 0 | 0 | - | - | - |
| EBIT | -9.78 | -6.11 | -6.94 | -1.44 | -1.02 | -0.03 |
| Revenue as Reported | 2.24 | 2.1 | 0.05 | - | - | - |
| Advertising Expenses | - | 0.75 | 0.36 | - | 0 | 0.01 |
Source: S&P Capital IQ. Standard template.
Financial Sources.